Pharmaceuticals

Projected Growth of the Global Rare Kidney Diseases Market to Reach $14.21 Billion by 2029

December 3, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the rare kidney diseases market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Rare Kidney Diseases Market By The End Of 2029?

The dipeptide peptidase 4 inhibitors market size has demonstrated consistent expansion in recent years. It is projected to grow from $11.3 billion in 2024 to $11.81 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.5%. The market’s past growth can be ascribed to improved access to diabetes treatments, expanding indications for DPP-4 inhibitors beyond type 2 diabetes, increased utilization of DPP-4 inhibitors in triple therapy regimens, a growing geriatric population, an increasing emphasis on healthcare, a rising focus on disease prevention, the proliferation of oral anti-diabetic drugs, and their greater adoption in primary care settings.

The dipeptide peptidase 4 inhibitors market is projected to experience sustained expansion over the coming years. This market is anticipated to reach $14.21 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 4.7%. Factors contributing to this growth during the forecast period include the rising incidence of type 2 diabetes, a surging need for efficient diabetes care, the impact of an aging demographic on diabetes rates, a greater emphasis on tailored medical treatments, and the expanding use of DPP-4 inhibitors in developing economies. Additionally, the increasing occurrence of diabetes and its associated complications, coupled with a general rise in demand for diabetes management, are driving this expansion. Key developments expected during this timeframe involve strategic collaborations, new product authorizations, and continuous investments in research and development.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15791&type=smp

Which Business Drivers Are Underpinning The Growth Of The Rare Kidney Diseases Market?

The increasing occurrence of diabetes is projected to fuel the expansion of the dipeptide peptidase 4 inhibitors market in the coming years. Diabetes is a persistent medical condition impacting how the body processes glucose (sugar), an essential energy source for the body’s cells. The rise in diabetes cases is primarily attributed to the widespread adoption of inactive lifestyles and poor dietary habits in modern societies. Dipeptidyl peptidase 4 inhibitors are employed in diabetes treatment to enhance glycemic control through inhibiting the breakdown of incretin hormones. For example, in 2024, as reported by the International Diabetes Federation, a Belgium-based health organization, 537 million adults (1 in 10) were living with diabetes in 2021, a number anticipated to climb to 643 million by 2030 and further to 783 million by 2045. Consequently, the escalating prevalence of diabetes serves as a significant impetus for the dipeptide peptidase 4 inhibitors market.

What Are The Principal Segment Types In The Rare Kidney Diseases Market?

The dipeptide peptidase 4 inhibitors market covered in this report is segmented –

1) By Type: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin, Others Types

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Channels

3) By Application: Type 2 Diabetes, Gestational Diabetes, Metabolic Syndrome, Other Applications

Which Companies Are Contributing Significantly To The Rare Kidney Diseases Market Growth?

Major companies operating in the dipeptide peptidase 4 inhibitors market are Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Macleods Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corp., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Cadila Healthcare Limited, Lupin Limited, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Limited, Biocon Limited, LG Life Sciences, USV Private Limited, Sanwa Kagaku Kenkyusho Co. Ltd., Kowa Company Ltd

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/dipeptide-peptidase-4-inhibitors-global-market-report

Which Region Offers The Most Opportunity For Rare Kidney Diseases Market Expansion?

Asia-Pacific was the largest region in the dipeptide peptidase 4 inhibitors market in 2024. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dipeptide peptidase 4 inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=15791&type=smp

Browse Through More Reports Similar to the Global Rare Kidney Diseases Market 2025, By The Business Research Company

Her2 Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report

Checkpoint Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Protein Inhibitor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795